<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p&gt;&lt;table id="schedule" cellspacing="0" cellpadding="2" summary="This table shows the date, time, and location of the meeting" border="0" style="width: 643px"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;th id="a1" valign="top" align="left" bgcolor="#cccccc" style="width: 71px"&gt;Center&lt;/th&gt;&lt;th id="a2" valign="top" align="left" bgcolor="#cccccc" style="width: 158px"&gt;Date&lt;/th&gt;&lt;th id="a3" valign="top" align="left" bgcolor="#cccccc" style="width: 172px"&gt;Time&lt;/th&gt;&lt;th id="a4" valign="top" align="left" bgcolor="#cccccc" style="width: 238px"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" headers="a1" height="61" style="width: 71px"&gt;CDER&lt;/td&gt;&lt;td valign="top" headers="a2" style="width: 158px"&gt;January 20-21, 2010&lt;br /&gt;&amp;nbsp;&lt;/td&gt;&lt;td valign="top" headers="a3" style="width: 172px"&gt;Day 1: 8:00 a.m. to 5:00 p.m.&lt;br /&gt;Day 2: 8:00 a.m. to 12:00 noon&lt;/td&gt;&lt;td valign="top" headers="a4" style="width: 238px"&gt;&lt;p&gt;FDA White Oak Campus&lt;br /&gt;Building 31&lt;br /&gt;The Great Room (Rm. 1503)&lt;br /&gt;White Oak Conference Center&lt;br /&gt;10903 New Hampshire Avenue&lt;br /&gt;Silver Spring, Maryland&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/p&gt;&lt;h4&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;/h4&gt;&lt;p&gt;On January 20, 2011, the committee will discuss new drug application (NDA) 202-008, florbetapir F 18 injection, sponsored by Avid Radiopharmaceuticals, Inc., proposed for use in positron emission tomography (PET) imaging of &amp;beta;-amyloid (beta-amyloid) aggregates in the brain to help rule out Alzheimer's disease.&lt;/p&gt;&lt;p&gt;On January 21, 2011, the committee will discuss NDA 201-277, gadobutrol injection, sponsored by Bayer HealthCare Pharmaceuticals, proposed for use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity (abnormal blood supply and circulation) of the central nervous system. The BBB is an area consisting of specialized cells that restrict passage of certain molecules from the bloodstream into the brain.&lt;/p&gt;&lt;h4&gt;Meeting Materials&lt;/h4&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt;&lt;p&gt;Background Material&lt;/p&gt;&lt;ul sizset="26" sizcache="1"&gt;&lt;li sizset="26" sizcache="1"&gt;&lt;a target="" href="[!--$wcmUrl('link','ucm235850.htm')--]"&gt;2010 Meeting Materials, Peripheral and Central Nervous System Drugs Advisory Committee&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;h4&gt;Public Participation Information&lt;/h4&gt;&lt;p&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Written submissions may be made to the contact person on or before January 5, 2011.&lt;/li&gt;&lt;li&gt;Oral presentations from the public will be scheduled between approximately 1:30 p.m. and 2:30 p.m. on January 20, 2011 and 10 a.m. to 11 a.m. on January 21, 2011. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before December 27, 2010.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by December 28, 2010.&lt;/p&gt;&lt;h4&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/h4&gt;&lt;ul sizset="27" sizcache="1"&gt;&lt;li sizset="27" sizcache="1"&gt;Diem-Kieu Ngo&lt;br /&gt;Center for Drug Evaluation and Research&amp;nbsp;&lt;br /&gt;Food and Drug Administration&lt;br /&gt;WO31-2417&lt;br /&gt;10903 New Hampshire Avenue&lt;br /&gt;Silver Spring, MD 20993-0002&lt;br /&gt;Phone: 301-796-9001&lt;br /&gt;Fax: 301-847-8533&lt;br /&gt;E-mail:&amp;nbsp;&lt;a href="mailto:diem.ngo@fda.hhs.gov"&gt;diem.ngo@fda.hhs.gov&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138&lt;br /&gt;(301-443-0572 in the Washington DC area)&lt;br /&gt;Code: 3014512543&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency&amp;rsquo;s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt;&lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. Information regarding special accommodations due to a disability, visitor parking and transportation may be accessed at: &lt;a target="" href="[!--$wcmUrl('link','ucm220308.htm')--]"&gt;White Oak Conference Center Parking and Transportation Information for FDA Advisory Committee Meetings&lt;/a&gt;. If you require special accommodations due to a disability, please contact Diem-Kieu Ngo at (301) 796-9001 at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings.&lt;/p&gt;&lt;p sizset="28" sizcache="1"&gt;Please visit our Web site at &lt;a target="" href="[!--$wcmUrl('link','ucm111462.htm')--]"&gt;Public Conduct During FDA Advisory Committee Meetings&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).&lt;/p&gt;</wcm:element>
</wcm:root>
